Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: A cohort study

Urologia Internationalis

Volumn 87, Issue 1, 2011, Pages 49-53

  Rouse, Paul ^a   Shaw, Greg ^a   Ahmed, Hashim U ^a,d   Freeman, Alex ^c   Allen, Clare ^b   Emberton, Mark ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Department of Academic Radiology ^*  (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d Division of Surgery and Interventional Science   (United Kingdom)

Author keywords

Likelihood ratio; Magnetic resonance imaging; Negative predictive value; Positive predictive value; Prostate biopsy; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; LONDON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNNECESSARY PROCEDURES;

EID: 80051792047     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000325880     Document Type: Article

References (20)

1. Holmström B, et al: Prostate specific antigen for early detection of prostate cancer: Longitudinal study. BMJ 2009; 339:b3537.
2. Djavan B, et al: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4; when should we stop? J Urol 2001; 166: 1679-1683.
3. Schröder FH, et al: Screening and prostatecancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
4. Bill-Axelson A, et al: Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-1154.
5. Cooperberg MR, et al: The changing face of prostate cancer. J Clin Oncol 2005; 23: 8146-8151. (Pubitemid 46211547)
6. Ahmed HU, et al: Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009; 6: 197-206.
7. Puech P, et al: Dynamic contrast-enhancedmagnetic resonance imaging evaluation of intraprostatic prostate cancer: Correlation with radical prostatectomy specimens. Urology 2009; 74: 1094-1099.
8. Goto Y, et al: Distinguishing clinically important from unimportant prostate cancer before treatment. J Urol 1996; 156: 1059-1063. (Pubitemid 26269829)
9. Ahmed HU: The index lesion and the origin of prostate cancer. N Engl J Med 2009; 361: 1704-1706.
10. Harnden P, et al: The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression? A systematic review and metaanalysis. Cancer 2008; 112: 971-981. (Pubitemid 351304580)
11. O'Donnell H, Parker C: What is low-risk prostate cancer and what is its natural history? World J Urol 2008; 26: 415-422.
12. Stark JR, et al: Gleason score and lethal prostate cancer: Does 3 + 4 = 4 + 3? J Clin Oncol 2009; 27: 3459-3464.
13. Kirkham AP, et al: How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006; 50: 1163-1174.
14. Kumar R, et al: Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: A follow-up study. Urology 2008; 72: 859-863.
15. Squillaci E, et al: MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res 2005; 24: 523-530. (Pubitemid 43139544)
16. Chen M, et al: Prostate cancer detection: Comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol 2008; 49: 602-610.
17. Tanimoto A, et al: Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25: 146-152. (Pubitemid 46095209)
18. Bossuyt PM, et al: Comparative accuracy: Assessing new tests against existing diagnostic pathways. BMJ 2006; 332: 1089-1092. (Pubitemid 44365494)
19. Onik G, et al: Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27: 4321-4326.
20. Ahmed HU, et al: Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007; 4: 632-642. (Pubitemid 350020378)